IP Group’s Enterprise Therapeutics Reports Positive Phase 1 Results for Inhaled ENaC Blocker ETD001 in Cystic Fibrosis

Reuters12-09

IP Group's Enterprise <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Phase 1 Results for Inhaled ENaC Blocker ETD001 in Cystic Fibrosis

Enterprise Therapeutics, a portfolio company of IP Group plc, has published results from its Phase 1 clinical trial of ETD001, a novel inhaled epithelial sodium channel (ENaC) blocker for the treatment of cystic fibrosis. The study, published in The Journal of Cystic Fibrosis, demonstrated that ETD001 was well tolerated in healthy participants at doses higher than those predicted to be therapeutic, with no significant changes in blood potassium levels observed. The pharmacokinetic profile indicated prolonged lung retention and potential for extended duration of action. A Phase 2 trial of ETD001 in people with cystic fibrosis is currently in progress, with headline data expected in early 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on December 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590538340?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 23:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590538340","market":"us","top_or_hot":-1,"title":"IP Group’s Enterprise Therapeutics Reports Positive Phase 1 Results for Inhaled ENaC Blocker ETD001 in Cystic Fibrosis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IP Group's Enterprise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Phase 1 Results for Inhaled ENaC Blocker ETD001 in Cystic Fibrosis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Enterprise Therapeutics, a portfolio company of IP Group plc, has published results from its Phase 1 clinical trial of ETD001, a novel inhaled epithelial sodium channel (ENaC) blocker for the treatment of cystic fibrosis. The study, published in The Journal of Cystic Fibrosis, demonstrated that ETD001 was well tolerated in healthy participants at doses higher than those predicted to be therapeutic, with no significant changes in blood potassium levels observed. The pharmacokinetic profile indicated prolonged lung retention and potential for extended duration of action. A Phase 2 trial of ETD001 in people with cystic fibrosis is currently in progress, with headline data expected in early 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on December 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IP Group’s Enterprise Therapeutics Reports Positive Phase 1 Results for Inhaled ENaC Blocker ETD001 in Cystic Fibrosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIP Group’s Enterprise Therapeutics Reports Positive Phase 1 Results for Inhaled ENaC Blocker ETD001 in Cystic Fibrosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-09 23:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IP Group's Enterprise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Phase 1 Results for Inhaled ENaC Blocker ETD001 in Cystic Fibrosis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Enterprise Therapeutics, a portfolio company of IP Group plc, has published results from its Phase 1 clinical trial of ETD001, a novel inhaled epithelial sodium channel (ENaC) blocker for the treatment of cystic fibrosis. The study, published in The Journal of Cystic Fibrosis, demonstrated that ETD001 was well tolerated in healthy participants at doses higher than those predicted to be therapeutic, with no significant changes in blood potassium levels observed. The pharmacokinetic profile indicated prolonged lung retention and potential for extended duration of action. A Phase 2 trial of ETD001 in people with cystic fibrosis is currently in progress, with headline data expected in early 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on December 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPO.UK","symbol_name":"IP GROUP","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL5J4VwP:1","article_id":"2590538340","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590538340","pubTimestamp":1765294498,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Enterprise Therapeutics, a portfolio company of IP Group plc, has published results from its Phase 1 clinical trial of ETD001, a novel inhaled epithelial sodium channel  blocker for the treatment of cystic fibrosis. The study, published in The Journal of Cystic Fibrosis, demonstrated that ETD001 was well tolerated in healthy participants at doses higher than those predicted to be therapeutic, with no significant changes in blood potassium levels observed. The pharmacokinetic profile indicated prolonged lung retention and potential for extended duration of action. A Phase 2 trial of ETD001 in people with cystic fibrosis is currently in progress, with headline data expected in early 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPO.UK":"IP GROUP","BK5078":"资产管理与托管银行"},"translate_title":"IP Group旗下Enterprise Therapeutics报告吸入ENaC阻断剂ETD001治疗囊性纤维化的1期积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPO.UK":0.9},"content_text":"IP Group's Enterprise Therapeutics Reports Positive Phase 1 Results for Inhaled ENaC Blocker ETD001 in Cystic Fibrosis\n    \n\n        Enterprise Therapeutics, a portfolio company of IP Group plc, has published results from its Phase 1 clinical trial of ETD001, a novel inhaled epithelial sodium channel (ENaC) blocker for the treatment of cystic fibrosis. The study, published in The Journal of Cystic Fibrosis, demonstrated that ETD001 was well tolerated in healthy participants at doses higher than those predicted to be therapeutic, with no significant changes in blood potassium levels observed. The pharmacokinetic profile indicated prolonged lung retention and potential for extended duration of action. A Phase 2 trial of ETD001 in people with cystic fibrosis is currently in progress, with headline data expected in early 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on December 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590538340","isCrawlerRequest":true}